⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 4, 2026Clinical and Molecular HepatologyOpen Access

Preclinical pharmacology and toxicology study of an AAV8-tATP7B vector for Wilson’s disease

Z. Wang Mengyu Wang Mengyuan Wu Lei Ye Tianwen Lou Xuxu Sun Wenzheng Zhao Fang Liu Tianyi Ren Wuping Li Jian-Gao Fan

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the efficacy and safety of the AAV8-tATP7B vector for treating Wilson’s disease.
Conducted preclinical pharmacology and toxicology assessments of AAV8-tATP7B.
Evaluated vector efficacy in relevant animal models.
Assessed safety profiles through toxicological studies.
AAV8-tATP7B demonstrated effective targeting and correction of Wilson’s disease pathology.
Safety assessments indicated a favorable profile with minimal adverse effects.

Implication

Preclinical pharmacology and toxicology study shows efficacy and safety for AAV8-tATP7B in Wilson’s Disease, indicating potential for clinical use.

Abstract

These results establish the efficacy and safety profile of AAV8-tATP7B and provide the rationale for its clinical translation in patients with WD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/69abc0de5af8044f7a4e98db https://doi.org/10.3350/cmh.2025.1300

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long-Term Correction of Copper Metabolism in Wilson's Disease Mice with AAV8 Vector Delivering Truncated ATP7Bpreclinical · 2019 · 27 citations
2101. Toxicology and Biodistribution Studies of a Recombinant Adeno-Associated Virus 2 (rAAV2) Alpha-1 Antitrypsin (AAT) Vectorpreclinical · 2004 · 12 citations
3728. Safety and Bioactivity of rAAV2-hAAT in alpha-1 Antitrypsin-Deficient Patients in a Phase I Clinical Trialcohort · 2006
4Preclinical Characterization of A Recombinant Adeno-Associated Virus Type 1-Pseudotyped Vector Demonstrates Dose-Dependent Injection Site Inflammation And Dissemination of Vector Genomes to Distant Sitespreclinical · 2007 · 50 citations
5Non-Clinical Study Examining AAV8.TBG.hLDLR Vector-Associated Toxicity in Chow-Fed Wild-Type and LDLR +/− Rhesus Macaquespreclinical · 2017 · 57 citations

More related papers

Development of an adipose-tropic AAV capsid ablating liver tropism2024
Prevalence of adeno-associated virus type 3B neutralizing antibodies in cohorts of healthy donors and Wilson’s disease adults2026
The AAV Vector Toolkit: Poised at the Clinical Crossroads2012

More from Clinical and Molecular Hepatology

Epigenetic and Epitranscriptomic Regulation of Immune Checkpoint Response in Hepatocellular Carcinoma: Mechanisms, Therapeutic Targeting, and Translational ChallengesWed,
Immunotherapy and targeted therapy plus hepatic arterial infusion chemotherapy for HCC with portal vein tumor thrombosis (CHANCE2504): a nationwide target trial emulation studyWed,